Platinum hitches a ride with sulfur in the Earth s crust esrf.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from esrf.fr Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Grapheal Raises EUR1.9 Million to Advance Development of Embedded Biosensing Technology and Application in Digital COVID Testing and Wound Monitoring
February 9, 2021 GMT
GRENOBLE, France (BUSINESS WIRE) Feb 9, 2021
Grapheal, a developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, announced today that it has raised a total of EUR1.9 million in equity and non-dilutive sources, including seed financing from Novalis Biotech’s Acceleration Fund, several innovation grants, and Bpifrance convertible notes and loans.
ADVERTISEMENT
The funds will be used to advance the industrialization of Grapheal’s flexible graphene-based biosensor technology. This sensing technology combines novel electronic nanomaterials, embedded wireless electronics, software data analysis, and medical cloud IoT technologies. The first two applications of the technolo
Grapheal raises €1.9m to develop graphene-based biosensors
The Grapheal team. Image: Grapheal
The medtech start-up will use the funds to support the development of a digital Covid-19 test and wound-monitoring biosensors.
As the pandemic continues, many start-ups in the health space have seen an influx of investment. According to Pitchbook’s European Venture Report for 2020, investment in biotech and pharma start-ups jumped by more than 40pc year-on-year.
Now, a French medtech company specialising in graphene-based wearable sensors has secured €1.9m in equity and non-dilutive sources.
Founded in 2019, Grapheal develops wearable and disposable sensors that enable continuous monitoring and diagnosis. The company is a spin-out from the Neel Institute at the French National Centre for Scientific Research.